Erythropoietin in plastic surgery

• Published in: Handchirurgie, Mikrochirurgie, plastische Chirurgie Vol. 45; no. 2; p. 108
• Main Authors: Günter, C I, Rezaeian, F, Harder, Y, Lohmeyer, J A, Egert, S, Bader, A, Schilling, A F, Machens, H-G
• Format: Journal Article
• Language: German
• Published: Germany 01.04.2013
• Subjects: Anemia - drug therapy; Anemia - physiopathology; Chronic Disease; Clinical Trials as Topic; Erythropoietin - adverse effects; Erythropoietin - physiology; Erythropoietin - therapeutic use; Graft Survival - drug effects; Graft Survival - physiology; Humans; Nerve Regeneration - drug effects; Nerve Regeneration - physiology; Reconstructive Surgical Procedures - methods; Regenerative Medicine - methods; Skin - injuries; Surgical Flaps - physiology; Surgical Flaps - surgery; Wound Healing - drug effects; Wound Healing - physiology; Wounds and Injuries - physiopathology; Wounds and Injuries - surgery
• ISSN: 1439-3980
• DOI: 10.1055/s-0033-1334909

EPO is an autologous hormone, which is known to regulate erythropoiesis. For 30 years it has been used for the therapy of diverse forms of anaemia, such as renal anaemia, tumour-related anaemias, etc. Meanwhile, a multitude of scientific publications were able to demonstrate its pro-regenerative effects after trauma. These include short-term effects such as the inhibition of the "primary injury response" or apoptosis, and mid- and long-term effects for example the stimulation of stem cell recruitment, growth factor production, angiogenesis and re-epithelialisation. Known adverse reactions are increases of thromboembolic events and blood pressure, as well as a higher mortality in patients with tumour anaemias treated with EPO. Scientific investigations of EPO in the field of plastic surgery included: free and local flaps, nerve regeneration, wound healing enhancement after dermal thermal injuries and in chronic wounds.Acute evidence for the clinical use of EPO in the field of plastic surgery is still not satisfactory, due to the insufficient number of Good Clinical Practice (GCP)-conform clinical trials. Thus, the initiation of more scientifically sound trials is indicated.